NLRP3 and Parkinson disease: NLRP3/Cas-1 modulators could selectively suppress inflammation caused by the NLRP3 inflammasome, either by directly targeting NLRP3 and NLRP3-dependent pathways (NF-kB pathway and ROS synthesis) or by inhibiting regulatory proteins involved in PD neurodegeneration, such as caspase-1 [67].